Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Surg. 1998 Aug;176(2):172-5.

Clinical benchmark for healing of chronic venous ulcers. Venous Ulcer Study Collaborators.

Author information

  • 1Division of Vascular Surgery, Montefiore Medical Center, and the Albert Einstein College of Medicine, New York, New York, USA.

Abstract

BACKGROUND:

To determine the results of standardized ulcer treatment regimes and effects of the oral thromboxane A2 antagonist Ifetroban (250 mg daily) on healing of chronic lower-extremity venous stasis ulcers.

METHODS:

In a prospective, randomized, double blind, placebo-controlled multicenter study, 165 patients were randomized to Ifetroban (n = 83) versus placebo (n = 82) for a period of 12 weeks. Both groups were treated with sustained graduated compression and hydrocolloid. Ulcer size was measured weekly by tracings and computerized planimetry. A total of 150 patients completed the study.

RESULTS:

Complete ulcer healing was achieved after 12 weeks in 55% of patients receiving Ifetroban and in 54% of those taking a placebo with no significant differences; 84% of ulcers in both groups achieved greater than 50% area reduction in size.

CONCLUSIONS:

These results are likely to be useful as a benchmark for comparison with other treatment protocols concerning the care of chronic lower-extremity stasis ulcers.

PMID:
9737626
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk